H.Amdt.224 - An amendment numbered 5 printed in House Report 116-61 to Commission a study by the National Academy of Medicine into the amount of federal funding and research used in the development of drugs by pharmaceutical companies, and to put measures in place to curb excessive drug costs.
About This Bill
Passed
Latest Action · May 16, 2019
On agreeing to the DeSaulnier amendment (A005) Agreed to by voice vote.